A Phase Ib/II Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330, Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Phase of Trial: Phase I/II
Latest Information Update: 08 Apr 2017
At a glance
- Drugs Selinexor (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 31 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 31 Jan 2017 Status changed from recruiting to suspended.